Australia and the UK plan a health genomics memorandum and set out life sciences commitments
Statements published on November 18 cover clinical trials, medicines regulation and isotopes for cancer therapies, after talks held in September.
By Science Desk ·
Australia and the United Kingdom plan a memorandum of understanding on health genomics between NHS England and the Australian Government Department of Health, Disability and Ageing, according to a communiqué the UK government published on November 18, 2026. It appeared alongside a joint statement on life sciences and biotechnology that lists commitments by regulators, trade agencies, innovation bodies and industry groups in both countries.
Both documents follow the second Australia-UK Strategic Innovation Dialogue, held in Sydney and Canberra on September 14-16, 2026, under the innovation chapter of the two countries' free trade agreement. Officials from Australia's Department of Industry, Science and Resources and the UK's Department for Business, Innovation, Science and Trade co-chaired it. The first dialogue took place in London in April 2024, and the two sides look ahead to the next one in 2028.
Genomics, trials and regulators
The life sciences statement, which records a meeting of the two governments' representatives in Canberra on September 15, names clinical trials, genomics and precision medicine, biotechnology, digital health, advanced therapies, regulation and routes to commercialization among the areas of cooperation. In the dialogue, the two sides compared how they bring genomics into health care, from governance and data infrastructure to workforce and fair access, and exchanged views on genomic data, artificial intelligence, regulation and public trust. NHS England representatives also plan a visit to Australia.
| Organizations | Commitments in the statement |
|---|---|
| TGA and MHRA (medicines regulators) | Continue to collaborate, bilaterally and through the Access Consortium with Canada, Singapore and Switzerland; share experience on new regulatory approaches; keep implementing the mutual recognition agreement on medical device conformity assessment |
| Austrade and the UK Department for Business, Innovation, Science and Trade | Promote trade, investment and company links in clinical trials, genomics, health data, digital health, biotechnology, medical technology and advanced therapies |
| AUScelerate and UK Catapult centers | Continue collaborations in cell and gene therapies, radiopharmaceuticals, isotope supply and molecular imaging |
| AusBiotech and the UK BioIndustry Association | Continue industry links through policy work, investor networks and support for cross-border partnerships |
Isotopes for cancer therapies
Several of the projects the statement names concern nuclear medicine. The UK's Medicines Discovery Catapult is working with Australian partners, through Innovate UK's Sustainable Medicines Manufacturing Innovation program, on a secure supply of lead-212 for targeted alpha therapies. With support from AUScelerate, it also collaborates with entX, whose nuclear medicine brand Isomedica is developing ways to recover isotopes from low-level radioactive waste and supply starting materials for nuclear medicine; the statement says the collaboration has given the Catapult access to materials for radiotherapy development and for research into cancer therapies. The Cell and Gene Therapy Catapult has helped an Australian company show its cell therapy production systems in the UK and analyzed market access for an Australian university group working on a stem cell treatment for heart failure; the statement names neither.
Beyond health
The communiqué ranges wider. It notes research interests in quantum technologies, semiconductors and photonics, talks on research security and on future framework program priorities, including the design and scope of Framework Programme 10, and exchanges on offshore wind and grid digitalization. On positioning, navigation and timing, both governments recognized the need for a multi-layered approach to resilience and pointed to risks to the global geodetic supply chain, including to observatories, specialist staff and the spectrum that geodetic observations depend on. Geoscience Australia and the UK's National Physical Laboratory are working toward a memorandum on calibrating and validating Earth observation data.
The two countries also welcomed the conclusion of negotiations on Australia's association to Horizon Europe; The Next News reported on the association agreement on November 14. Neither the communiqué nor the joint statement gives funding amounts, and most of the commitments describe work already under way rather than new programs (our reading of the two documents).
Sources
- Australia-United Kingdom Joint Communiqué on the 2nd Strategic Innovation Dialogue Department for Business, Innovation, Science and Trade (GOV.UK) gov.uk
- Joint statement between Australia and the UK on life sciences and biotechnology cooperation Department for Business, Innovation, Science and Trade (GOV.UK) gov.uk
Checked against the 2 sources above on November 18, 2026. Spotted an error? Tell us.